We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+19.28%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$8.67B
AUM Growth
+$1.11B
Cap. Flow
+$178M
Cap. Flow %
2.05%
Top 10 Hldgs %
55.18%
Holding
87
New
9
Increased
9
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$177M
2
ARTV
Artiva Biotherapeutics
ARTV
+$114M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$51.1M
4
BIOA
BioAge Labs
BIOA
+$44.3M
5
PCVX icon
Vaxcyte
PCVX
+$43.7M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$88.9M
2
VRNA
Verona Pharma
VRNA
+$64.6M
3
GERN icon
Geron
GERN
+$63.3M
4
ASND icon
Ascendis Pharma A/S
ASND
+$53.7M
5
URGN icon
UroGen Pharma
URGN
+$51.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
26
LENZ Therapeutics
LENZ
$166M
$99.2M 1.14%
4,178,823
– –
PEPG icon
27
PepGen
PEPG
$122M
$91.4M 1.05%
10,689,545
– –
AXSM icon
28
Axsome Therapeutics
AXSM
$11.2B
$89.9M 1.04%
1,000,000
– –
GPCR icon
29
Structure Therapeutics
GPCR
$3.41B
$83.2M 0.96%
1,896,772
– –
TRML
30
DELISTED
Tourmaline Bio
TRML
$65.3M 0.75%
2,538,925
– –
DNTH icon
31
Dianthus Therapeutics
DNTH
$5.84B
$63.9M 0.74%
2,333,000
– –
MLYS icon
32
Mineralys Therapeutics
MLYS
$2.25B
$58.7M 0.68%
4,850,984
– –
ACRV icon
33
Acrivon Therapeutics
ACRV
$64.2M
$58.4M 0.67%
8,340,508
– –
ATXS
34
DELISTED
Astria Therapeutics
ATXS
$56.2M 0.65%
5,105,213
+61,457
+1% +$683K
FDMT icon
35
4D Molecular Therapeutics
FDMT
$532M
$55.1M 0.64%
5,098,211
– –
CGON icon
36
CG Oncology
CGON
$6.28B
$52.7M 0.61%
1,397,433
– –
BCYC
37
Bicycle Therapeutics
BCYC
$269M
$51M 0.59%
2,253,000
– –
NKTX icon
38
Nkarta
NKTX
$150M
$48.8M 0.56%
10,805,129
– –
BIOA
39
BioAge Labs
BIOA
$402M
$46M 0.53%
+2,210,589
New +$44.3M
GHRS icon
40
GH Research
GHRS
$1.93B
$44.7M 0.52%
6,686,689
+85,000
+1% +$872K
PRAX icon
41
Praxis Precision Medicines
PRAX
$8.58B
$43.8M 0.51%
761,955
-473,644
-38% -$25.6M
IDYA icon
42
IDEAYA Biosciences
IDYA
$3.42B
$42.7M 0.49%
+1,347,252
New +$51.1M
LRMR icon
43
Larimar Therapeutics
LRMR
$397M
$39.6M 0.46%
6,045,351
– –
MBX
44
MBX Biosciences
MBX
$3.14B
$39.3M 0.45%
+1,511,334
New +$34.6M
ABOS icon
45
Acumen Pharmaceuticals
ABOS
$155M
$37M 0.43%
14,932,063
– –
FULC icon
46
Fulcrum Therapeutics
FULC
$273M
$36.5M 0.42%
10,229,099
-1,380,605
-12% -$10.2M
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
$32.5M 0.37%
3,184,711
-332,548
-9% -$5.07M
SLDB icon
48
Solid Biosciences
SLDB
$794M
$30.2M 0.35%
4,330,446
– –
CCCC icon
49
C4 Therapeutics
CCCC
$385M
$27.8M 0.32%
4,878,000
– –
ELVN icon
50
Enliven Therapeutics
ELVN
$3.92B
$27.1M 0.31%
1,061,233
-1,061,232
-50% -$24.6M
1
2
3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, RA Capital Management held 87 positions worth $8.67B, up 15% from $7.56B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management's Q3 2024 filing shows 9 new, 9 increased, 14 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 6,955,993 shares worth $177M. The largest sale was Longboard Pharmaceuticals, Inc. Common Stock, an estimated $88.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q3 2024 buy was Bicara Therapeutics: 6,955,993 shares worth $177M.
  • RA Capital Management added most to Vaxcyte in Q3 2024, an estimated $43.7M increase.
  • RA Capital Management's biggest Q3 2024 reduction was Verona Pharma, cutting an estimated $64.6M.
  • RA Capital Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q3 2024, selling an estimated $88.9M.
  • RA Capital Management's ten largest holdings make up 55% of its $8.67B portfolio in Q3 2024.
  • RA Capital Management opened 9 new positions and closed 6 in Q3 2024.
  • RA Capital Management's portfolio value rose 15% quarter-over-quarter to $8.67B.

Based on RA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.